XPA binds to the Replication Protein A (RPA) and is a core component of the nucleotide excision repair pathway. XPA is involved in one of the complementation groups of the heritable condition Xeroderma pigmentosum, where defects in nucleotide excision repair result in increased susceptibility to mutagens including UV.
| Inventor | Institute |
|---|---|
| Rick Wood | Cancer Research UK, London Research Institute: Lincoln's Inn Fields |
| Cat. #: | 152930 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Genetics |
| Application: | IHC ; IF ; WB |
| Target: | XPA |
| Reactivity: | Human |
| Clone: | 2A4 |
| Host: | Mouse |
| Class: | Monoclonal |
| Alternate name: | DNA repair protein complementing XP A cells, DNA repair protein complementing XP-A cells, DNA repair protein complementing XPA cells, Excision repair controlling, Xeroderma pigmentosum 1, Xeroderma pigmentosum complementation group A, Xeroderma pigmentosum group A complementing protein, Xeroderma pigmentosum group A-complementing protein, XP 1, XP1, xpa, Xpac |
|---|---|
| Product description: | XPA binds to the Replication Protein A (RPA) and is a core component of the nucleotide excision repair pathway. XPA is involved in one of the complementation groups of the heritable condition Xeroderma pigmentosum, where defects in nucleotide excision repair result in increased susceptibility to mutagens including UV. |
| Conjugation: | Unconjugated |
| Isotype: | IgG1 |
| Immunogen: | His-tagged recombinant human XPA protein. |
| Target background: | XPA binds to the Replication Protein A (RPA) and is a core component of the nucleotide excision repair pathway. XPA is involved in one of the complementation groups of the heritable condition Xeroderma pigmentosum, where defects in nucleotide excision repair result in increased susceptibility to mutagens including UV. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | -15° C to -25° C |
| Shipping conditions: | Dry ice |
| References: |
HCMV-infected cells maintain efficient nucleotide excision repair of the viral genome while abrogating repair of the host genome. O'Dowd et al. 2012. PLoS Pathog. 8(11):e1003038. PMID: 23209410. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151016 | Anti-CyclinA [E72.1] |
Key Info
Anti-CyclinA [E72.1]
|
View Tool | |||||||||||||||||||
| 151029 | Anti-HSVICP8 [11E2] |
Key Info
Anti-HSVICP8 [11E2]
|
View Tool | |||||||||||||||||||
| 151031 | Anti-RuvA [RuvA 12C6] |
Key Info
Anti-RuvA [RuvA 12C6]
|
View Tool | |||||||||||||||||||
| 151035 | Anti-CD8 [14] mAb |
Key Info
Anti-CD8 [14] mAb
|
View Tool | |||||||||||||||||||
| 151020 | Anti-CyclinB1 [V143.1] |
Key Info
Anti-CyclinB1 [V143.1]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.